Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial Officer

Published: 2026-04-16 11:21:09 ET PRME

Published on 04/16/2026 at 11:21 am EDT

Prime Medicine, Inc. announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine?s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. Ms. Makhni brings over 20 years of experience across multiple biotechnology and healthcare CFO and investment banking roles.

Prior to joining Prime Medicine, she served as CFO of Marengo Therapeutics, a clinical-stage immuno-oncology company, where she led all aspects of the finance organization, including business development, investor relations and corporate development. In this role, Ms. Makhni played a key role in the execution of multiple high-value strategic partnerships, including transactions with Ipsen and Gilead Sciences. Previously, Ms. Makhni served as CFO of Escient Pharmaceuticals and CFO and Head of Operations at Bierman ABA.

Earlier in her career, Ms. Makhni spent over a decade in investment banking and financial services at BMO Capital Markets, Goldman Sachs, Westbrook Partners and The Blackstone Group, advising public and private companies on equity and debt financings, mergers and acquisitions, and other strategic transactions. Ms. Makhni holds an M.B.A. from Harvard Business School and a B.S. from the Wharton School of the University of Pennsylvania.